Cycling cancer persister cells arise from lineages with distinct programsYaara Oren, Aviv Regev, Sara A. Hurvitz et al.|Nature|2021Cited by 514
Identifying genotype-dependent efficacy of single and combined PI3K- and MAPK-pathway inhibition in cancerMartin L. Sos, Roman K. Thomas, Stefanie Fischer et al.|Proceedings of the National Academy of Sciences|2009Cited by 255
Mammalian SWI/SNF chromatin remodeling complexes promote tyrosine kinase inhibitor resistance in EGFR-mutant lung cancerFernando J. de Miguel, Katerina Politi|Cancer Cell|2023Cited by 103
Challenges and opportunities for modeling aging and cancerOlga Anczuków, Karolina Palucka, Susie Airhart et al.|Cancer Cell|2023Cited by 24
ASCL1 Drives Tolerance to Osimertinib in <i>EGFR</i> Mutant Lung Cancer in Permissive Cellular ContextsBomiao Hu, Katerina Politi|Cancer Research|2024Cited by 24